Have established cardiovascular (CV) disease or are at risk for a first CV event
Have angiographic evidence of coronary artery disease on screening CCTA
If taking lipid-lowering medications, inclusive of statins or prescription strength niacin and PCSK9 inhibitors, these should be stable for 8 weeks
You may not be if
Have had a major CV event less than 60 days before measurement of the Lp(a) level used for eligibility or uncontrolled high blood pressure at screening
Have moderate to severe renal dysfunction
Have severe heart failure
Have a history of coronary artery bypass graft surgery (CABG)
Have a planned coronary angiography, percutaneous coronary intervention (PCI), coronary artery bypass graft, or valvular intervention
Have had a procedure to remove lipoproteins from the blood or received therapy specifically targeting Lp(a)
Are unable to safely undergo CCTA due to medication intolerance, contrast allergies, or anatomical/technical factors
Clareo Health | A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
